Rat Galectin-1 ELISA Kit EZ-Set (DIY Antibody Pairs) (antibody pairs and standards for assay development). Quantitate Rat Lgals1 in cell culture supernatants, serum and plasma (heparin, EDTA). Sensitivity: 10 pg/ml.
Product Type:
Antibodies Primary
Immunogen:
Expression system for standard: E.coli; Immunogen sequence: A2-E135
Applications:
ELISA
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Rat FGF21 ELISA Kit EZ-Set (DIY Antibody Pairs) (antibody pairs and standards for assay development). Quantitate Rat FGF21 in cell culture supernatants, serum and plasma (heparin, EDTA). Sensitivity: 10 pg/ml.
Product Type:
Antibodies Primary
Immunogen:
Expression system for standard: E.coli; Immunogen sequence: Y30-S208
Applications:
ELISA
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Rat Myostatin/GDF8 ELISA Kit (96 Tests). Quantitate Rat MSTN in cell culture supernatants, tissue, serum and plasma (heparin or EDTA). Sensitivity: 10pg/ml.
Product Type:
Assay & Detection
Storage Temp:
Mixed
Immunogen:
Expression system for standard: NS0; Immunogen sequence: D268-S376
Applications:
ELISA
Additional Info:
For quantitative detection of rat Myostatin/GDF8 in cell culture supernatants, tissue, serum and plasma(heparin, EDTA).
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Rat MMP-2 Quick ELISA Kit (90 minutes, 96 Tests). Quantitate Rat Mmp2 in cell culture supernatants, serum and plasma (heparin). Sensitivity: 10pg/ml.
Product Type:
Assay & Detection
Storage Temp:
Mixed
Immunogen:
Expression system for standard: NS0; Immunogen sequence: A30-C662
Applications:
ELISA
Additional Info:
The Quick ELISA kits, assay takes less than 1.5 hours. Detect Rat MMP-2 with <10pg/ml sensitivity Compatible samples: cell culture supernatants, serum and plasma (heparin). This is a TMB colorimetric sandwich ELISA kit with short assay time and quick experiment set up.
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Rat Lipocalin-2/NGAL Quick ELISA Kit (90 minutes, 96 Tests). Quantitate Rat Lcn2 in cell culture supernatants, serum, plasma (heparin) and urine. Sensitivity: 10pg/ml.
Product Type:
Assay & Detection
Storage Temp:
Mixed
Immunogen:
Expression system for standard: NS0; Immunogen sequence: Q21-N198
Applications:
ELISA
Additional Info:
The Quick ELISA kits, assay takes less than 1.5 hours. Detect Rat Lipocalin-2/NGAL with <10pg/ml sensitivity Compatible samples: cell culture supernatants, serum, plasma (heparin) and urine. This is a TMB colorimetric sandwich ELISA kit with short assay time and quick experiment set up.
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Rat FABP3 ELISA Kit EZ-Set (DIY Antibody Pairs) (antibody pairs and standards for assay development). Quantitate Rat Fabp3 in cell culture supernatants, serum and plasma (heparin, EDTA). Sensitivity: 10 pg/ml.
Product Type:
Antibodies Primary
Immunogen:
Expression system for standard: E.coli; Immunogen sequence: A2-A133
Applications:
ELISA
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Rat EGF Quick ELISA Kit (90 minutes, 96 Tests). Quantitate Rat Egf in cell culture supernatants, serum, plasma (heparin, EDTA) and urine. Sensitivity: 1pg/ml.
Product Type:
Assay & Detection
Storage Temp:
Mixed
Immunogen:
Expression system for standard: E.coli; Immunogen sequence: N974-R1026
Applications:
ELISA
Additional Info:
The Quick ELISA kits, assay takes less than 1.5 hours. Detect Rat EGF with <1pg/ml sensitivity Compatible samples: cell culture supernatants, serum, plasma (heparin, EDTA) and urine. This is a TMB colorimetric sandwich ELISA kit with short assay time and quick experiment set up.
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Vimentin is a component of intermediate filament in mesenchymal cells, such as endothelial cells, fibroblasts, lymphocytes, and melanocytes. Anti-Vimentin is useful for assessing whether tissue samples have been processed and preserved properly. A panel of Anti-Vimentin and Anti-Keratin is useful for differentiating melanomas from large cell lymphomas and undifferentiated carcinomas. This diagnostic grade Vimentin IVD antibody stains melanomas and schwannomas, as well as endometrial endometrioid adenocarcinomas.
Rat CXCL4/PF4 ELISA Kit EZ-Set (DIY Antibody Pairs) (antibody pairs and standards for assay development). Quantitate Rat Pf4 in cell culture supernatants, serum and plasma (heparin, EDTA). Sensitivity: 15 pg/ml.
Product Type:
Antibodies Primary
Immunogen:
Expression system for standard: E.coli; Immunogen sequence: V30-S105
Applications:
ELISA
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Rat CXCL1 ELISA Kit EZ-Set (DIY Antibody Pairs) (antibody pairs and standards for assay development). Quantitate Rat Cxcl1 in cell culture supernatants, serum and plasma (EDTA). Sensitivity: 1 pg/ml.
Product Type:
Antibodies Primary
Immunogen:
Expression system for standard: E.coli; Immunogen sequence: A25-K96
Applications:
ELISA
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Rat CRP/C Reactive Protein ELISA Kit (96 Tests). Quantitate Rat Crp in cell culture supernatants, cell lysates, serum and plasma (heparin, EDTA). Sensitivity: 10pg/ml.
Product Type:
Assay & Detection
Storage Temp:
Mixed
Immunogen:
Expression system for standard: NS0; Immunogen sequence: H20-S230
Applications:
ELISA
Additional Info:
For quantitative detection of rat CRP in cell culture supernatants, cell lysates, serum and plasma (heparin, EDTA).
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Vimentin is a component of intermediate filament in mesenchymal cells, such as endothelial cells, fibroblasts, lymphocytes, and melanocytes. Anti-Vimentin is useful for assessing whether tissue samples have been processed and preserved properly. A panel of Anti-Vimentin and Anti-Keratin is useful for differentiating melanomas from large cell lymphomas and undifferentiated carcinomas. This diagnostic grade Vimentin IVD antibody stains melanomas and schwannomas, as well as endometrial endometrioid adenocarcinomas.
The PRAME [IHC092] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC092
GMDN Code:
65250
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The PRAME [IHC092] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC092
GMDN Code:
65250
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The PRAME [IHC092] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC092
GMDN Code:
65250
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Podoplanin is a transmembrane mucoprotein specifically expressed in the endothelium of lymphatic capillaries, while remaining absent from the blood vasculature. The protein is co-localized with VEGFR3/FLT4 in normal skin and kidney. Anti-Podoplanin is useful in the identification of lymphangiomas, Kaposi's sarcomas, epithelioid mesotheliomas, hemangioblastomas, seminomas, and some angiosarcomas that likely have lymphatic differentiation.
Podoplanin is a transmembrane mucoprotein specifically expressed in the endothelium of lymphatic capillaries, while remaining absent from the blood vasculature. The protein is co-localized with VEGFR3/FLT4 in normal skin and kidney. Anti-Podoplanin is useful in the identification of lymphangiomas, Kaposi's sarcomas, epithelioid mesotheliomas, hemangioblastomas, seminomas, and some angiosarcomas that likely have lymphatic differentiation.
Podoplanin is a transmembrane mucoprotein specifically expressed in the endothelium of lymphatic capillaries, while remaining absent from the blood vasculature. The protein is co-localized with VEGFR3/FLT4 in normal skin and kidney. Anti-Podoplanin is useful in the identification of lymphangiomas, Kaposi's sarcomas, epithelioid mesotheliomas, hemangioblastomas, seminomas, and some angiosarcomas that likely have lymphatic differentiation.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
Postmeiotic Segregation Increased 2 (PMS2) is a DNA repair protein involved in mismatch repair. Mutations and deficiencies in the PMS2 gene have been linked to microsatellite instability and malignancies such as hereditary nonpolyposis colorectal cancer and endometrial cancer. Expression levels of the PMS2 protein may be useful as a screening tool for Lynch syndrome after a colorectal cancer diagnosis. Anti-PMS2 is recommended to be used as part of a panel along with antibodies against MSH2, MSH6, and MLH1.
The PLAP [IHC088] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC088
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Placenta
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The PLAP [IHC088] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC088
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Placenta
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The PLAP [IHC088] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC088
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Placenta
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
Perforin, a pore-forming protein found in the granules of cytotoxic T-lymphocytes and natural killer cells, functions to enable granzymes to enter the target cells and activate apoptosis. Perforin expression is upregulated in activated CD8+ T-cells, and these cells have been identified to have a major influence in Th1-associated inflammatory skin diseases. It has been suggested that perforin plays a role in alloimmunity, being involved in both the cytolytic process of rejection as well as downregulation of the T-cell mediated responses associated with the alloimmune response. Perforin-mediated cytotoxicity has also been linked to a number of autoimmune diseases.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC646
Antibody Isotype:
IgG1
GMDN Code:
63737
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Perforin, a pore-forming protein found in the granules of cytotoxic T-lymphocytes and natural killer cells, functions to enable granzymes to enter the target cells and activate apoptosis. Perforin expression is upregulated in activated CD8+ T-cells, and these cells have been identified to have a major influence in Th1-associated inflammatory skin diseases. It has been suggested that perforin plays a role in alloimmunity, being involved in both the cytolytic process of rejection as well as downregulation of the T-cell mediated responses associated with the alloimmune response. Perforin-mediated cytotoxicity has also been linked to a number of autoimmune diseases.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC646
Antibody Isotype:
IgG1
GMDN Code:
63737
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Perforin, a pore-forming protein found in the granules of cytotoxic T-lymphocytes and natural killer cells, functions to enable granzymes to enter the target cells and activate apoptosis. Perforin expression is upregulated in activated CD8+ T-cells, and these cells have been identified to have a major influence in Th1-associated inflammatory skin diseases. It has been suggested that perforin plays a role in alloimmunity, being involved in both the cytolytic process of rejection as well as downregulation of the T-cell mediated responses associated with the alloimmune response. Perforin-mediated cytotoxicity has also been linked to a number of autoimmune diseases.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC646
Antibody Isotype:
IgG1
GMDN Code:
63737
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC441
Antibody Isotype:
IgG1, kappa
GMDN Code:
62046
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil, Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC441
Antibody Isotype:
IgG1, kappa
GMDN Code:
62046
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil, Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC441
Antibody Isotype:
IgG1, kappa
GMDN Code:
62046
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil, Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC411
Antibody Isotype:
IgG
GMDN Code:
62046
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC411
Antibody Isotype:
IgG
GMDN Code:
62046
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Programmed Death-Ligand 1 (PD-L1), CD274, or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC411
Antibody Isotype:
IgG
GMDN Code:
62046
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The PD-L1-TEC [IHC451] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissue within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC451
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Lung Adenocarcinoma
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The PD-L1-TEC [IHC451] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissue within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC451
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Lung Adenocarcinoma
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The PD-L1-TEC [IHC451] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissue within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC451
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Lung Adenocarcinoma
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The PD-L1-IMF [IHC461] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissue within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC461
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Lung Adenocarcinoma
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The PD-L1-IMF [IHC461] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissue within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC461
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Lung Adenocarcinoma
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The PD-L1-IMF [IHC461] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissue within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC461
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Lung Adenocarcinoma
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
The PCNA [IHC711] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
The PCNA [IHC711] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
The PCNA [IHC711] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
Parathyroid Hormone (PTH), also known as Parathormone or Parathyrin, is a hormone secreted by the parathyroid glands that functions to increase the concentration of calcium in the blood. Anti-Parathyroid Hormone (PTH) is useful for differentiating parathyroid hyperplasia/neoplasms from thyroid and metastatic neoplasms, and is also used in the consideration of parathyroid carcinomas located primarily in the anterior mediastinum.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC645
Antibody Isotype:
IgM
GMDN Code:
63169
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Parathyroid Tissue
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Parathyroid Hormone (PTH), also known as Parathormone or Parathyrin, is a hormone secreted by the parathyroid glands that functions to increase the concentration of calcium in the blood. Anti-Parathyroid Hormone (PTH) is useful for differentiating parathyroid hyperplasia/neoplasms from thyroid and metastatic neoplasms, and is also used in the consideration of parathyroid carcinomas located primarily in the anterior mediastinum.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC645
Antibody Isotype:
IgM
GMDN Code:
63169
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Parathyroid Tissue
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Parathyroid Hormone (PTH), also known as Parathormone or Parathyrin, is a hormone secreted by the parathyroid glands that functions to increase the concentration of calcium in the blood. Anti-Parathyroid Hormone (PTH) is useful for differentiating parathyroid hyperplasia/neoplasms from thyroid and metastatic neoplasms, and is also used in the consideration of parathyroid carcinomas located primarily in the anterior mediastinum.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC645
Antibody Isotype:
IgM
GMDN Code:
63169
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Parathyroid Tissue
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p504s, also known as ?-Methylacyl Coenzyme A Racemase (AMACR), is an enzyme localized in the peroxisome and mitochondria that functions in ?-oxidation of branched chain fatty acids, as well as bile synthesis. AMACR has been clinically indicated as a tissue biomarker for prostate cancer and colorectal cancer, as well as high-grade prostatic intraepithelial neoplasia, a precursor lesion of prostate cancer. p504s overexpression has also been detected in a number of other cancers including ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma.
p504s, also known as ?-Methylacyl Coenzyme A Racemase (AMACR), is an enzyme localized in the peroxisome and mitochondria that functions in ?-oxidation of branched chain fatty acids, as well as bile synthesis. AMACR has been clinically indicated as a tissue biomarker for prostate cancer and colorectal cancer, as well as high-grade prostatic intraepithelial neoplasia, a precursor lesion of prostate cancer. p504s overexpression has also been detected in a number of other cancers including ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma.
p504s, also known as ?-Methylacyl Coenzyme A Racemase (AMACR), is an enzyme localized in the peroxisome and mitochondria that functions in ?-oxidation of branched chain fatty acids, as well as bile synthesis. AMACR has been clinically indicated as a tissue biomarker for prostate cancer and colorectal cancer, as well as high-grade prostatic intraepithelial neoplasia, a precursor lesion of prostate cancer. p504s overexpression has also been detected in a number of other cancers including ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC058
Antibody Isotype:
IgG1
GMDN Code:
64957
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Squamous Cell Carcinoma of Lung
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC058
Antibody Isotype:
IgG1
GMDN Code:
64957
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Squamous Cell Carcinoma of Lung
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC058
Antibody Isotype:
IgG1
GMDN Code:
64957
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Squamous Cell Carcinoma of Lung
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC128
GMDN Code:
57500
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC128
GMDN Code:
57500
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC128
GMDN Code:
57500
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p21, also known as p21^ Cip1 ^ , p21^ Waf1 ^, Cyclin-Dependent Kinase Inhibitor 1, or CDK-Interacting Protein 1, functions to regulate cell cycle progression at G1 by inhibiting the activity of Cyclin-CDK2 or -CDK4 complexes. This cyclin-dependent kinase inhibitor is expressed in all adult human tissues, and decreased expression of p21 is linked to poor prognosis in a number of carcinomas including gastric carcinoma, non-small cell lung carcinoma, and thyroid carcinoma. p21 is also associated with favourable prognosis in several tumours.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC021
GMDN Code:
57493
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p21, also known as p21^ Cip1 ^ , p21^ Waf1 ^, Cyclin-Dependent Kinase Inhibitor 1, or CDK-Interacting Protein 1, functions to regulate cell cycle progression at G1 by inhibiting the activity of Cyclin-CDK2 or -CDK4 complexes. This cyclin-dependent kinase inhibitor is expressed in all adult human tissues, and decreased expression of p21 is linked to poor prognosis in a number of carcinomas including gastric carcinoma, non-small cell lung carcinoma, and thyroid carcinoma. p21 is also associated with favourable prognosis in several tumours.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC021
Antibody Isotype:
IgG1, kappa
GMDN Code:
57493
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p21, also known as p21^ Cip1 ^ , p21^ Waf1 ^, Cyclin-Dependent Kinase Inhibitor 1, or CDK-Interacting Protein 1, functions to regulate cell cycle progression at G1 by inhibiting the activity of Cyclin-CDK2 or -CDK4 complexes. This cyclin-dependent kinase inhibitor is expressed in all adult human tissues, and decreased expression of p21 is linked to poor prognosis in a number of carcinomas including gastric carcinoma, non-small cell lung carcinoma, and thyroid carcinoma. p21 is also associated with favourable prognosis in several tumours.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC021
Antibody Isotype:
IgG1, kappa
GMDN Code:
57493
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC120
Antibody Isotype:
IgG1
GMDN Code:
62843
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Lobular Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC120
Antibody Isotype:
IgG1
GMDN Code:
62843
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Lobular Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC120
Antibody Isotype:
IgG1
GMDN Code:
62843
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Lobular Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
Octamer-Binding Transcription Factor 4 (Oct-4), also known as POU5F1 (POU Domain, Class 5, Transcription Factor 1), is a member of the POU homeodomain family of transcription factors and is involved in the maintenance and regulation of pluripotency in embryonic stem and germ cells. Anti-Oct-4 is highly useful and sensitive for seminomas, germinoma, dysgerminoma, embryonal carcinoma, and gonadoblastoma. Oct-4 may be associated with tumourigenesis, and can have an effect on some aspects of tumour behavior, including tumour recurrence or resistance to therapies.
Octamer-Binding Transcription Factor 4 (Oct-4), also known as POU5F1 (POU Domain, Class 5, Transcription Factor 1), is a member of the POU homeodomain family of transcription factors and is involved in the maintenance and regulation of pluripotency in embryonic stem and germ cells. Anti-Oct-4 is highly useful and sensitive for seminomas, germinoma, dysgerminoma, embryonal carcinoma, and gonadoblastoma. Oct-4 may be associated with tumourigenesis, and can have an effect on some aspects of tumour behavior, including tumour recurrence or resistance to therapies.
Octamer-Binding Transcription Factor 4 (Oct-4), also known as POU5F1 (POU Domain, Class 5, Transcription Factor 1), is a member of the POU homeodomain family of transcription factors and is involved in the maintenance and regulation of pluripotency in embryonic stem and germ cells. Anti-Oct-4 is highly useful and sensitive for seminomas, germinoma, dysgerminoma, embryonal carcinoma, and gonadoblastoma. Oct-4 may be associated with tumourigenesis, and can have an effect on some aspects of tumour behavior, including tumour recurrence or resistance to therapies.
Neurotrophic tyrosine kinase receptor (NTRK) is a family of 3 proto-oncogenes including NTRK1, NTRK2, and NTRK3. NTRK gene fusions have been reported in a variety of tumor types, which are involved in biological processes such as neuronal survival, differentiation, and plasticity under physiological circumstances. Recently, FDA has approved ENtrectinib for patients with NTRK fusions, thus testing for NTRK fusions identifies patients who may be candidates for NTRK inhibitor therapy.
Neurotrophic tyrosine kinase receptor (NTRK) is a family of 3 proto-oncogenes including NTRK1, NTRK2, and NTRK3. NTRK gene fusions have been reported in a variety of tumor types, which are involved in biological processes such as neuronal survival, differentiation, and plasticity under physiological circumstances. Recently, FDA has approved ENtrectinib for patients with NTRK fusions, thus testing for NTRK fusions identifies patients who may be candidates for NTRK inhibitor therapy.
Neurotrophic tyrosine kinase receptor (NTRK) is a family of 3 proto-oncogenes including NTRK1, NTRK2, and NTRK3. NTRK gene fusions have been reported in a variety of tumor types, which are involved in biological processes such as neuronal survival, differentiation, and plasticity under physiological circumstances. Recently, FDA has approved ENtrectinib for patients with NTRK fusions, thus testing for NTRK fusions identifies patients who may be candidates for NTRK inhibitor therapy.
Neuron-Specific Enolase (NSE), also known as Enolase 2 (ENO2), is one of three enolase enzymes found in mammals, and acts as a phosphopyruvate hydratase. This mammalian glycolytic isoenzyme is located specifically in neurons of neuroendocrine cells, as well as tumours associated with those neurons. However, it has also been detected immunohistochemically in non-neoplastic cells of the pituitary, peptide-secreting tissues, pinealocytes, neuroendocrine cells of the lung, thyroid, parafollicular cells, adrenal medulla, islets of Langerhans, Merkel cells of the skin, and melanocytes. NSE is a useful marker for identifying normal striated muscle, hepatocytes, and peripheral nerves. Anti-NSE may detect for neuroendocrine differentiation, only when used in a panel of antibodies including more specific markers such as synaptophysin, chromogranin, and neurofilament.
Neuron-Specific Enolase (NSE), also known as Enolase 2 (ENO2), is one of three enolase enzymes found in mammals, and acts as a phosphopyruvate hydratase. This mammalian glycolytic isoenzyme is located specifically in neurons of neuroendocrine cells, as well as tumours associated with those neurons. However, it has also been detected immunohistochemically in non-neoplastic cells of the pituitary, peptide-secreting tissues, pinealocytes, neuroendocrine cells of the lung, thyroid, parafollicular cells, adrenal medulla, islets of Langerhans, Merkel cells of the skin, and melanocytes. NSE is a useful marker for identifying normal striated muscle, hepatocytes, and peripheral nerves. Anti-NSE may detect for neuroendocrine differentiation, only when used in a panel of antibodies including more specific markers such as synaptophysin, chromogranin, and neurofilament.
Neuron-Specific Enolase (NSE), also known as Enolase 2 (ENO2), is one of three enolase enzymes found in mammals, and acts as a phosphopyruvate hydratase. This mammalian glycolytic isoenzyme is located specifically in neurons of neuroendocrine cells, as well as tumours associated with those neurons. However, it has also been detected immunohistochemically in non-neoplastic cells of the pituitary, peptide-secreting tissues, pinealocytes, neuroendocrine cells of the lung, thyroid, parafollicular cells, adrenal medulla, islets of Langerhans, Merkel cells of the skin, and melanocytes. NSE is a useful marker for identifying normal striated muscle, hepatocytes, and peripheral nerves. Anti-NSE may detect for neuroendocrine differentiation, only when used in a panel of antibodies including more specific markers such as synaptophysin, chromogranin, and neurofilament.
Neurofilaments are a group of intermediate filaments found abundantly around the axons of vertebrate neurons. They are also expressed in paragangliomas, adrenal pheochromocytomas, Merkel cell tumours, carcinoid tumours, neuroendocrine carcinomas of the skin, and oat cell carcinomas of the lung. Anti-Neurofilament stains a variety of neural, neuroendocrine, and endocrine tumours, such as neuromas, ganglioneuromas, gangliogliomas, ganglioneuroblastomas, and neuroblastomas.
Neurofilaments are a group of intermediate filaments found abundantly around the axons of vertebrate neurons. They are also expressed in paragangliomas, adrenal pheochromocytomas, Merkel cell tumours, carcinoid tumours, neuroendocrine carcinomas of the skin, and oat cell carcinomas of the lung. Anti-Neurofilament stains a variety of neural, neuroendocrine, and endocrine tumours, such as neuromas, ganglioneuromas, gangliogliomas, ganglioneuroblastomas, and neuroblastomas.
Neurofilaments are a group of intermediate filaments found abundantly around the axons of vertebrate neurons. They are also expressed in paragangliomas, adrenal pheochromocytomas, Merkel cell tumours, carcinoid tumours, neuroendocrine carcinomas of the skin, and oat cell carcinomas of the lung. Anti-Neurofilament stains a variety of neural, neuroendocrine, and endocrine tumours, such as neuromas, ganglioneuromas, gangliogliomas, ganglioneuroblastomas, and neuroblastomas.
The Nestin [IHC105] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC105
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Glioma
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The Nestin [IHC105] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC105
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Glioma
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The Nestin [IHC105] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC105
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Glioma
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
Nerve Growth Factor Receptor (NGFR), also known as p75, P-75NTR, or CD271, is a neurotrophin receptor belonging to the tumour necrosis factor receptor family. It is expressed mainly in Schwann cells and neurons, as well as a number of other non-neuronal cell types, and is also expressed in melanocytes, melanomas, neuroblastomas, pheochromocytomas, neurofibromas, neurotized nevi (type C melanocytes), and other neural crest cell or tumour derivatives. It has been suggested that NGFR may act as a tumour suppressor indicated in prostate and urothelial cancer, and Anti-NGFR is often used in adjunct with S100, to aid in the diagnosis of desmoplastic and neurotrophic malignant melanomas. Anti-NGFR is also useful as an aid in the diagnosis of breast malignancy, as the antibody labels the myoepithelial cells of breast ducts and intralobular fibroblasts of breast ducts.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC637
Antibody Isotype:
IgG1, kappa
GMDN Code:
57471
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Nerve Growth Factor Receptor (NGFR), also known as p75, P-75NTR, or CD271, is a neurotrophin receptor belonging to the tumour necrosis factor receptor family. It is expressed mainly in Schwann cells and neurons, as well as a number of other non-neuronal cell types, and is also expressed in melanocytes, melanomas, neuroblastomas, pheochromocytomas, neurofibromas, neurotized nevi (type C melanocytes), and other neural crest cell or tumour derivatives. It has been suggested that NGFR may act as a tumour suppressor indicated in prostate and urothelial cancer, and Anti-NGFR is often used in adjunct with S100, to aid in the diagnosis of desmoplastic and neurotrophic malignant melanomas. Anti-NGFR is also useful as an aid in the diagnosis of breast malignancy, as the antibody labels the myoepithelial cells of breast ducts and intralobular fibroblasts of breast ducts.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC637
Antibody Isotype:
IgG1, kappa
GMDN Code:
57471
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Nerve Growth Factor Receptor (NGFR), also known as p75, P-75NTR, or CD271, is a neurotrophin receptor belonging to the tumour necrosis factor receptor family. It is expressed mainly in Schwann cells and neurons, as well as a number of other non-neuronal cell types, and is also expressed in melanocytes, melanomas, neuroblastomas, pheochromocytomas, neurofibromas, neurotized nevi (type C melanocytes), and other neural crest cell or tumour derivatives. It has been suggested that NGFR may act as a tumour suppressor indicated in prostate and urothelial cancer, and Anti-NGFR is often used in adjunct with S100, to aid in the diagnosis of desmoplastic and neurotrophic malignant melanomas. Anti-NGFR is also useful as an aid in the diagnosis of breast malignancy, as the antibody labels the myoepithelial cells of breast ducts and intralobular fibroblasts of breast ducts.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC637
Antibody Isotype:
IgG1, kappa
GMDN Code:
57471
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
N-cadherin, also known as Cadherin-2 (CDH2) or Neural Cadherin (NCAD), is a transmembrane cell adhesion molecule that was originally detected in nervous tissue. It plays an important role in embryogenesis, being involved in gastrulation and neural crest development. N-cadherin is found in cancer cells and allows for transendothelial migration, which is a critical process in the metastasis of cancer. Overexpression and disorderly arrangement of N-cadherin has been noted in dilated cardiomyopathy. It has been suggested that, when considered in adjunct with the status of a number of additional cell-cell adhesion molecules, missense mutations in N-cadherin may be a potential indicator of obsessive-compulsive disorder and Tourette disorder.
The C-FOS Antibody was raised to synthetic peptide sequence corresponding to human c-fos (4-17) coupled to bovine thyroglobulin with glutaraldehyde. For induction of c-fos protein activity rats were injected with 1.0 ml of 1.5 M NaCl per 100 grams of body weight. Negative control rats were injected with the same volume of normal saline. The ImmunoStar c-fos antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat paraventricular nucleus and supraoptic nucleus using indirect immunofluorescent and biotin/avidin-HRP techniques. No labeling was seen in negative control rats. Recommended primary dilutions for these methods are 1/200-1/400 in PBS/0.3% Triton X-100 - FITC Technique and 1/4000-1/6000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique. Specificity of the antiserum was demonstrated by blockage of staining in experimental rats by omission of c-fos antibody or by substitution of antibody pre-incubated with synthetic peptide or the conjugate. Immunoblot analysis of mediobasal hypothalamus showed a single band of approximately 55-60 kD.
N-cadherin, also known as Cadherin-2 (CDH2) or Neural Cadherin (NCAD), is a transmembrane cell adhesion molecule that was originally detected in nervous tissue. It plays an important role in embryogenesis, being involved in gastrulation and neural crest development. N-cadherin is found in cancer cells and allows for transendothelial migration, which is a critical process in the metastasis of cancer. Overexpression and disorderly arrangement of N-cadherin has been noted in dilated cardiomyopathy. It has been suggested that, when considered in adjunct with the status of a number of additional cell-cell adhesion molecules, missense mutations in N-cadherin may be a potential indicator of obsessive-compulsive disorder and Tourette disorder.
N-cadherin, also known as Cadherin-2 (CDH2) or Neural Cadherin (NCAD), is a transmembrane cell adhesion molecule that was originally detected in nervous tissue. It plays an important role in embryogenesis, being involved in gastrulation and neural crest development. N-cadherin is found in cancer cells and allows for transendothelial migration, which is a critical process in the metastasis of cancer. Overexpression and disorderly arrangement of N-cadherin has been noted in dilated cardiomyopathy. It has been suggested that, when considered in adjunct with the status of a number of additional cell-cell adhesion molecules, missense mutations in N-cadherin may be a potential indicator of obsessive-compulsive disorder and Tourette disorder.
Napsin A is a pepsin-like aspartic proteinase that is closely related to Napsin B. It is expressed mainly in the lung and kidney, and is involved in the correct folding, targeting, and control of aspartic proteinase zymogens. Napsin A expression has been indicated in type II pneumocytes and adenocarcinomas of the lung and kidney. Anti-Napsin A is also useful for differentiating between primary lung adenocarcinomas and adenocarcinomas of other organs, due to the high expression of Napsin A in adenocarcinomas of the lung.
Napsin A is a pepsin-like aspartic proteinase that is closely related to Napsin B. It is expressed mainly in the lung and kidney, and is involved in the correct folding, targeting, and control of aspartic proteinase zymogens. Napsin A expression has been indicated in type II pneumocytes and adenocarcinomas of the lung and kidney. Anti-Napsin A is also useful for differentiating between primary lung adenocarcinomas and adenocarcinomas of other organs, due to the high expression of Napsin A in adenocarcinomas of the lung.
Napsin A is a pepsin-like aspartic proteinase that is closely related to Napsin B. It is expressed mainly in the lung and kidney, and is involved in the correct folding, targeting, and control of aspartic proteinase zymogens. Napsin A expression has been indicated in type II pneumocytes and adenocarcinomas of the lung and kidney. Anti-Napsin A is also useful for differentiating between primary lung adenocarcinomas and adenocarcinomas of other organs, due to the high expression of Napsin A in adenocarcinomas of the lung.
Nanog is a homeoprotein that functions with pluripotent factors, such as Oct-4 and SOX2, to maintain embryonic stem cell pluripotency. Expression of this protein has been noted in seminoma, dysgerminoma, embryonal carcinoma, and other undifferentiated germ cell tumours, while Nanog expression is absent in normal adult organ tissues. Anti-Nanog may be useful in distinguishing between undifferentiated germ cell tumours and non-germ cell tumours.
Nanog is a homeoprotein that functions with pluripotent factors, such as Oct-4 and SOX2, to maintain embryonic stem cell pluripotency. Expression of this protein has been noted in seminoma, dysgerminoma, embryonal carcinoma, and other undifferentiated germ cell tumours, while Nanog expression is absent in normal adult organ tissues. Anti-Nanog may be useful in distinguishing between undifferentiated germ cell tumours and non-germ cell tumours.
Nanog is a homeoprotein that functions with pluripotent factors, such as Oct-4 and SOX2, to maintain embryonic stem cell pluripotency. Expression of this protein has been noted in seminoma, dysgerminoma, embryonal carcinoma, and other undifferentiated germ cell tumours, while Nanog expression is absent in normal adult organ tissues. Anti-Nanog may be useful in distinguishing between undifferentiated germ cell tumours and non-germ cell tumours.
Smooth Muscle-Myosin is a major component of smooth muscle contractile apparatus. IHC detection of Myosin, Smooth Muscle visulizes the myoepithelial cell present in both normal and in situ malignant breast and bronchioloalveolar lesions and serves a valuable biomarker to distinguish between benign and malignant tumors.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC091
GMDN Code:
57591
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Breast, Colon
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Smooth Muscle-Myosin is a major component of smooth muscle contractile apparatus. IHC detection of Myosin, Smooth Muscle visulizes the myoepithelial cell present in both normal and in situ malignant breast and bronchioloalveolar lesions and serves a valuable biomarker to distinguish between benign and malignant tumors.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC091
GMDN Code:
57591
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Breast, Colon
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Smooth Muscle-Myosin is a major component of smooth muscle contractile apparatus. IHC detection of Myosin, Smooth Muscle visulizes the myoepithelial cell present in both normal and in situ malignant breast and bronchioloalveolar lesions and serves a valuable biomarker to distinguish between benign and malignant tumors.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC091
GMDN Code:
57591
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Breast, Colon
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Myogenin belongs to a family of myogenic transcription factors, including MyoD, Myf5, and MRF4, which are critical in muscle development. Myogenin is found strictly in cells of skeletal muscle origin, and is therefore used as a biomarker for tumours of the muscle lineage, including alveolar rhabdomyosarcomas. Anti-Myogenin staining may occur in Wilms' tumour, and it labels the nuclei of myoblasts in developing muscle tissue. It is also expressed in some leiomyosarcomas.
Myogenin belongs to a family of myogenic transcription factors, including MyoD, Myf5, and MRF4, which are critical in muscle development. Myogenin is found strictly in cells of skeletal muscle origin, and is therefore used as a biomarker for tumours of the muscle lineage, including alveolar rhabdomyosarcomas. Anti-Myogenin staining may occur in Wilms' tumour, and it labels the nuclei of myoblasts in developing muscle tissue. It is also expressed in some leiomyosarcomas.
Myogenin belongs to a family of myogenic transcription factors, including MyoD, Myf5, and MRF4, which are critical in muscle development. Myogenin is found strictly in cells of skeletal muscle origin, and is therefore used as a biomarker for tumours of the muscle lineage, including alveolar rhabdomyosarcomas. Anti-Myogenin staining may occur in Wilms' tumour, and it labels the nuclei of myoblasts in developing muscle tissue. It is also expressed in some leiomyosarcomas.
Multiple Myeloma Oncogene-1 (MUM1), also known as Interferon Regulatory Factor 4 (IRF4), is a transcription factor present in a variety of hematolymphoid neoplasms and in malignant melanoma, but is absent from other human tumours. MUM1 expression has been indicated in both pediatric and adult diffuse large B-cell lymphoma (DLBCL), and, when the immunostaining status of CD10 and Bcl6 is also considered, Anti-MUM1 can be used to sub-distinguish germinal center type DLBCL from the non-germinal center type. Anti-MUM1 stains normal melanocytes, melanocytic nevi, and malignant melanoma in non-hematopoietic tissues, and can also stain other B-cell lymphomas such as lymphoplasmacytic lymphoma, grade 3 follicular lymphoma, primary central nervous system lymphoma, primary mediastinal large B-cell lymphoma, Burkitt-like lymphoma, and classic Hodgkin's lymphoma.
Multiple Myeloma Oncogene-1 (MUM1), also known as Interferon Regulatory Factor 4 (IRF4), is a transcription factor present in a variety of hematolymphoid neoplasms and in malignant melanoma, but is absent from other human tumours. MUM1 expression has been indicated in both pediatric and adult diffuse large B-cell lymphoma (DLBCL), and, when the immunostaining status of CD10 and Bcl6 is also considered, Anti-MUM1 can be used to sub-distinguish germinal center type DLBCL from the non-germinal center type. Anti-MUM1 stains normal melanocytes, melanocytic nevi, and malignant melanoma in non-hematopoietic tissues, and can also stain other B-cell lymphomas such as lymphoplasmacytic lymphoma, grade 3 follicular lymphoma, primary central nervous system lymphoma, primary mediastinal large B-cell lymphoma, Burkitt-like lymphoma, and classic Hodgkin's lymphoma.
Multiple Myeloma Oncogene-1 (MUM1), also known as Interferon Regulatory Factor 4 (IRF4), is a transcription factor present in a variety of hematolymphoid neoplasms and in malignant melanoma, but is absent from other human tumours. MUM1 expression has been indicated in both pediatric and adult diffuse large B-cell lymphoma (DLBCL), and, when the immunostaining status of CD10 and Bcl6 is also considered, Anti-MUM1 can be used to sub-distinguish germinal center type DLBCL from the non-germinal center type. Anti-MUM1 stains normal melanocytes, melanocytic nevi, and malignant melanoma in non-hematopoietic tissues, and can also stain other B-cell lymphomas such as lymphoplasmacytic lymphoma, grade 3 follicular lymphoma, primary central nervous system lymphoma, primary mediastinal large B-cell lymphoma, Burkitt-like lymphoma, and classic Hodgkin's lymphoma.
Mucin 6 (MUC6) is a glycoprotein expressed in mucous neck cells, pyloric glands of the antrum, epigastric and bronchial epithelium, and in Müller ducts of the endocervix and urethral epithelium. Anti-MUC6 is useful for differentiating fetal, precancerous, and cancerous colonic mucosa from normal colon, as the antibody does not stain the latter. Anti-MUC6 stains the gastric epithelial surface of normal human gastrointestinal tracts.
Mucin 6 (MUC6) is a glycoprotein expressed in mucous neck cells, pyloric glands of the antrum, epigastric and bronchial epithelium, and in Müller ducts of the endocervix and urethral epithelium. Anti-MUC6 is useful for differentiating fetal, precancerous, and cancerous colonic mucosa from normal colon, as the antibody does not stain the latter. Anti-MUC6 stains the gastric epithelial surface of normal human gastrointestinal tracts.
Mucin 6 (MUC6) is a glycoprotein expressed in mucous neck cells, pyloric glands of the antrum, epigastric and bronchial epithelium, and in Müller ducts of the endocervix and urethral epithelium. Anti-MUC6 is useful for differentiating fetal, precancerous, and cancerous colonic mucosa from normal colon, as the antibody does not stain the latter. Anti-MUC6 stains the gastric epithelial surface of normal human gastrointestinal tracts.
Mucin 5AC (MUC5AC) is a secretory-type mucin found in columnar mucous cells of surface gastric epithelium and in goblet cells of the fetal and precancerous colon, but not in normal colon cells. MUC5AC expression is indicated in carcinomas wherein the type is defined as diffuse and infiltrative, and those located mainly in the antrum. Studies have also suggested a correlation between MUC5AC and colorectal signet ring cell carcinoma, with overexpression of MUC5AC relating to the carcinogenesis, malignant potential, progression, and clinical behaviors.
Mucin 5AC (MUC5AC) is a secretory-type mucin found in columnar mucous cells of surface gastric epithelium and in goblet cells of the fetal and precancerous colon, but not in normal colon cells. MUC5AC expression is indicated in carcinomas wherein the type is defined as diffuse and infiltrative, and those located mainly in the antrum. Studies have also suggested a correlation between MUC5AC and colorectal signet ring cell carcinoma, with overexpression of MUC5AC relating to the carcinogenesis, malignant potential, progression, and clinical behaviors.
Mucin 5AC (MUC5AC) is a secretory-type mucin found in columnar mucous cells of surface gastric epithelium and in goblet cells of the fetal and precancerous colon, but not in normal colon cells. MUC5AC expression is indicated in carcinomas wherein the type is defined as diffuse and infiltrative, and those located mainly in the antrum. Studies have also suggested a correlation between MUC5AC and colorectal signet ring cell carcinoma, with overexpression of MUC5AC relating to the carcinogenesis, malignant potential, progression, and clinical behaviors.
The NRP1 [IHC121] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC122
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Brain
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The NRP1 [IHC121] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC122
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Brain
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The NRP1 [IHC121] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC122
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Brain
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
Mucin 1 (MUC1) is a membrane-bound glycoprotein involved in a number of protective and cell-signaling functions, including cell-cell adhesion, proliferation, motility, invasion, and survival. Overexpression of MUC1 is clinically indicated in breast carcinomas, papillary thyroid carcinomas, and thymic carcinomas, and reports have named MUC1 as a useful marker for differentiating thymic carcinoma from type B3 thymoma. The expression of MUC1 is correlated with the grade of malignancy in thymic epithelial tumours, and loss of MUC1 expression has been associated with reactive gastropathy. MUC1 is not expressed in normal human epidermis, but it has been detected in the epidermis of psoriatic plaques of biopsies from patients diagnosed with psoriasis vulgaris.
Mucin 1 (MUC1) is a membrane-bound glycoprotein involved in a number of protective and cell-signaling functions, including cell-cell adhesion, proliferation, motility, invasion, and survival. Overexpression of MUC1 is clinically indicated in breast carcinomas, papillary thyroid carcinomas, and thymic carcinomas, and reports have named MUC1 as a useful marker for differentiating thymic carcinoma from type B3 thymoma. The expression of MUC1 is correlated with the grade of malignancy in thymic epithelial tumours, and loss of MUC1 expression has been associated with reactive gastropathy. MUC1 is not expressed in normal human epidermis, but it has been detected in the epidermis of psoriatic plaques of biopsies from patients diagnosed with psoriasis vulgaris.
Mucin 1 (MUC1) is a membrane-bound glycoprotein involved in a number of protective and cell-signaling functions, including cell-cell adhesion, proliferation, motility, invasion, and survival. Overexpression of MUC1 is clinically indicated in breast carcinomas, papillary thyroid carcinomas, and thymic carcinomas, and reports have named MUC1 as a useful marker for differentiating thymic carcinoma from type B3 thymoma. The expression of MUC1 is correlated with the grade of malignancy in thymic epithelial tumours, and loss of MUC1 expression has been associated with reactive gastropathy. MUC1 is not expressed in normal human epidermis, but it has been detected in the epidermis of psoriatic plaques of biopsies from patients diagnosed with psoriasis vulgaris.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
MutS Homolog 2 (MSH2) is a protein involved in the mismatch-repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Expression levels of MSH2 are abnormally low in a high percentage of patients with microsatellite instability, as well as endometrial and ovarian cancers. Use of Anti-MSH2 is optimized when paired in an IHC panel with antibodies against MSH6, MLH1, and PMS2. Reports have shown Anti-MSH2 to be useful in the detection of the protein in a number of normal and neoplastic tissues, and for identifying a loss of MSH2 in tumours that are microsatellite-unstable.
MutS Homolog 2 (MSH2) is a protein involved in the mismatch-repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Expression levels of MSH2 are abnormally low in a high percentage of patients with microsatellite instability, as well as endometrial and ovarian cancers. Use of Anti-MSH2 is optimized when paired in an IHC panel with antibodies against MSH6, MLH1, and PMS2. Reports have shown Anti-MSH2 to be useful in the detection of the protein in a number of normal and neoplastic tissues, and for identifying a loss of MSH2 in tumours that are microsatellite-unstable.
MutS Homolog 2 (MSH2) is a protein involved in the mismatch-repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Expression levels of MSH2 are abnormally low in a high percentage of patients with microsatellite instability, as well as endometrial and ovarian cancers. Use of Anti-MSH2 is optimized when paired in an IHC panel with antibodies against MSH6, MLH1, and PMS2. Reports have shown Anti-MSH2 to be useful in the detection of the protein in a number of normal and neoplastic tissues, and for identifying a loss of MSH2 in tumours that are microsatellite-unstable.
MutL Homolog 1 (MLH1) is a protein involved in the mismatch-repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, as the MLH1 gene is frequently mutated in patients with this cancer. Studies have shown MLH1 to be deficient in a high percentage of patients with microsatellite instability, as well as endometrial and ovarian cancers. Use of Anti-MLH1 is optimized when paired in an IHC panel with MSH6, MSH2, and PMS2. Anti-MLH1 is useful in the detection of MLH1 in a number of normal and neoplastic tissues, and for identifying a loss of MLH1 in tumours that are microsatellite-unstable.
MutL Homolog 1 (MLH1) is a protein involved in the mismatch-repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, as the MLH1 gene is frequently mutated in patients with this cancer. Studies have shown MLH1 to be deficient in a high percentage of patients with microsatellite instability, as well as endometrial and ovarian cancers. Use of Anti-MLH1 is optimized when paired in an IHC panel with MSH6, MSH2, and PMS2. Anti-MLH1 is useful in the detection of MLH1 in a number of normal and neoplastic tissues, and for identifying a loss of MLH1 in tumours that are microsatellite-unstable.
MutL Homolog 1 (MLH1) is a protein involved in the mismatch-repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, as the MLH1 gene is frequently mutated in patients with this cancer. Studies have shown MLH1 to be deficient in a high percentage of patients with microsatellite instability, as well as endometrial and ovarian cancers. Use of Anti-MLH1 is optimized when paired in an IHC panel with MSH6, MSH2, and PMS2. Anti-MLH1 is useful in the detection of MLH1 in a number of normal and neoplastic tissues, and for identifying a loss of MLH1 in tumours that are microsatellite-unstable.
Multidrug Resistance 3 (MDR3), also known as ATP Binding Cassette Subfamily B Member 4 (ABCB4), is a membrane-associated protein belonging to the superfamily of ATP-binding cassette transporters. MDR3 is an energy-dependent phospholipid efflux translocator that mediates the translocation of phosphatidylcholine across the canalicular membrane of the hepatocyte, and also acts as a positive regulator of biliary lipid secretion. Defects in MDR3 are associated with progressive familial intrahepatic cholestasis type 3 and gallbladder disease type 1. Co-overexpression of MDR3 and MRP1 has been documented as correlating with blastemal subtype and high-risk prognosis of Wilms' tumour patients.
Multidrug Resistance 3 (MDR3), also known as ATP Binding Cassette Subfamily B Member 4 (ABCB4), is a membrane-associated protein belonging to the superfamily of ATP-binding cassette transporters. MDR3 is an energy-dependent phospholipid efflux translocator that mediates the translocation of phosphatidylcholine across the canalicular membrane of the hepatocyte, and also acts as a positive regulator of biliary lipid secretion. Defects in MDR3 are associated with progressive familial intrahepatic cholestasis type 3 and gallbladder disease type 1. Co-overexpression of MDR3 and MRP1 has been documented as correlating with blastemal subtype and high-risk prognosis of Wilms' tumour patients.
Multidrug Resistance 3 (MDR3), also known as ATP Binding Cassette Subfamily B Member 4 (ABCB4), is a membrane-associated protein belonging to the superfamily of ATP-binding cassette transporters. MDR3 is an energy-dependent phospholipid efflux translocator that mediates the translocation of phosphatidylcholine across the canalicular membrane of the hepatocyte, and also acts as a positive regulator of biliary lipid secretion. Defects in MDR3 are associated with progressive familial intrahepatic cholestasis type 3 and gallbladder disease type 1. Co-overexpression of MDR3 and MRP1 has been documented as correlating with blastemal subtype and high-risk prognosis of Wilms' tumour patients.
Mouse Double Minute 2 Homolog (MDM2), also known as HDM2 in humans, is crucial in negative regulation of the p53 tumour suppressor. Negative regulation is mediated through both the ubiquitination of p53/TP53, as well as inhibition of p53 transcriptional activation. Reports have indicated an overexpression of MDM2 to be associated with a number of different human tumour types, including soft tissue sarcomas, osteosarcomas, and breast tumours. When co-overexpressed with the CDK4 protein, MDM2 can also aid in the detection of well-differentiated liposarcomas and de-differentiated liposarcoma.
Mouse Double Minute 2 Homolog (MDM2), also known as HDM2 in humans, is crucial in negative regulation of the p53 tumour suppressor. Negative regulation is mediated through both the ubiquitination of p53/TP53, as well as inhibition of p53 transcriptional activation. Reports have indicated an overexpression of MDM2 to be associated with a number of different human tumour types, including soft tissue sarcomas, osteosarcomas, and breast tumours. When co-overexpressed with the CDK4 protein, MDM2 can also aid in the detection of well-differentiated liposarcomas and de-differentiated liposarcoma.
Mouse Double Minute 2 Homolog (MDM2), also known as HDM2 in humans, is crucial in negative regulation of the p53 tumour suppressor. Negative regulation is mediated through both the ubiquitination of p53/TP53, as well as inhibition of p53 transcriptional activation. Reports have indicated an overexpression of MDM2 to be associated with a number of different human tumour types, including soft tissue sarcomas, osteosarcomas, and breast tumours. When co-overexpressed with the CDK4 protein, MDM2 can also aid in the detection of well-differentiated liposarcomas and de-differentiated liposarcoma.
The MCT4 [IHC124] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC124
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Cervical Cancer
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The MCT4 [IHC124] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC124
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Cervical Cancer
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The MCT4 [IHC124] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of neoplastic tissues within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC124
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Cervical Cancer
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
MART-1, also known as Melan A or Melanoma Antigen Recognized by T-Cells 1, is a protein antigen found specifically on melanocytes of normal skin, retina, and nevi, and not in other normal tissues. Anti-MART-1 is therefore useful as a marker for melanocytic tumours, and as an aid in establishing the diagnosis of metastatic melanomas.
MART-1, also known as Melan A or Melanoma Antigen Recognized by T-Cells 1, is a protein antigen found specifically on melanocytes of normal skin, retina, and nevi, and not in other normal tissues. Anti-MART-1 is therefore useful as a marker for melanocytic tumours, and as an aid in establishing the diagnosis of metastatic melanomas.
MART-1, also known as Melan A or Melanoma Antigen Recognized by T-Cells 1, is a protein antigen found specifically on melanocytes of normal skin, retina, and nevi, and not in other normal tissues. Anti-MART-1 is therefore useful as a marker for melanocytic tumours, and as an aid in establishing the diagnosis of metastatic melanomas.
MART-1, also known as Melan A or Melanoma Antigen Recognized by T-Cells 1, is a protein antigen found specifically on melanocytes of normal skin, retina, and nevi, and not in other normal tissues. Anti-MART-1 is therefore useful as a marker for melanocytic tumours, and as an aid in establishing the diagnosis of metastatic melanomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC408
Antibody Isotype:
IgG1
GMDN Code:
57393
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Melanoma, Skin
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
MART-1, also known as Melan A or Melanoma Antigen Recognized by T-Cells 1, is a protein antigen found specifically on melanocytes of normal skin, retina, and nevi, and not in other normal tissues. Anti-MART-1 is therefore useful as a marker for melanocytic tumours, and as an aid in establishing the diagnosis of metastatic melanomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC408
Antibody Isotype:
IgG1
GMDN Code:
57393
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Melanoma, Skin
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
MART-1, also known as Melan A or Melanoma Antigen Recognized by T-Cells 1, is a protein antigen found specifically on melanocytes of normal skin, retina, and nevi, and not in other normal tissues. Anti-MART-1 is therefore useful as a marker for melanocytic tumours, and as an aid in establishing the diagnosis of metastatic melanomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC408
Antibody Isotype:
IgG1
GMDN Code:
57393
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Melanoma, Skin
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Luteinizing Hormone (LH) is a reproductive hormone produced and secreted by the gonadotropes in the anterior pituitary gland. LH functions to stimulate ovulation in females and the production of testosterone from the Leydig cells in males. This hormone is useful for the study of pituitary disease, and acts as a clinical marker that is useful for classifying tumours of the pituitary.
Luteinizing Hormone (LH) is a reproductive hormone produced and secreted by the gonadotropes in the anterior pituitary gland. LH functions to stimulate ovulation in females and the production of testosterone from the Leydig cells in males. This hormone is useful for the study of pituitary disease, and acts as a clinical marker that is useful for classifying tumours of the pituitary.
Luteinizing Hormone (LH) is a reproductive hormone produced and secreted by the gonadotropes in the anterior pituitary gland. LH functions to stimulate ovulation in females and the production of testosterone from the Leydig cells in males. This hormone is useful for the study of pituitary disease, and acts as a clinical marker that is useful for classifying tumours of the pituitary.
The Lp-PLA2 [IHC407] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of cardiovascular diseases within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC407
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil, Thymus, Placenta
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The Lp-PLA2 [IHC407] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of cardiovascular diseases within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC407
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil, Thymus, Placenta
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The Lp-PLA2 [IHC407] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of cardiovascular diseases within the context of antibody panels, the patients clinical history and other diagnostic tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC407
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Tonsil, Thymus, Placenta
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
LMO2, also known as LIM-Only Transcription Factor 2, RBTN2, or TTG2, is an oncoprotein that is expressed in normal germinal center B-cells, as well as bone marrow hematopoietic precursors and endothelial cells. LMO2 plays a role in angiogenesis and hematopoesis, and its expression has been detected in erythroid and myeloid precursors, megakaryocytes, and also in lymphoblastic and acute myeloid leukemias. LMO2 protein expression has been noted in diffuse large B-cell lymphoma, the most common adult non-Hodgkin's lymphoma, as well as follicular lymphoma, a neoplasm derived from germinal center B-cells that accounts for a number of cases of non-Hodgkin's lymphomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC615
Antibody Isotype:
IgG1, kappa
GMDN Code:
63898
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
LMO2, also known as LIM-Only Transcription Factor 2, RBTN2, or TTG2, is an oncoprotein that is expressed in normal germinal center B-cells, as well as bone marrow hematopoietic precursors and endothelial cells. LMO2 plays a role in angiogenesis and hematopoesis, and its expression has been detected in erythroid and myeloid precursors, megakaryocytes, and also in lymphoblastic and acute myeloid leukemias. LMO2 protein expression has been noted in diffuse large B-cell lymphoma, the most common adult non-Hodgkin's lymphoma, as well as follicular lymphoma, a neoplasm derived from germinal center B-cells that accounts for a number of cases of non-Hodgkin's lymphomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC615
Antibody Isotype:
IgG1, kappa
GMDN Code:
63898
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
LMO2, also known as LIM-Only Transcription Factor 2, RBTN2, or TTG2, is an oncoprotein that is expressed in normal germinal center B-cells, as well as bone marrow hematopoietic precursors and endothelial cells. LMO2 plays a role in angiogenesis and hematopoesis, and its expression has been detected in erythroid and myeloid precursors, megakaryocytes, and also in lymphoblastic and acute myeloid leukemias. LMO2 protein expression has been noted in diffuse large B-cell lymphoma, the most common adult non-Hodgkin's lymphoma, as well as follicular lymphoma, a neoplasm derived from germinal center B-cells that accounts for a number of cases of non-Hodgkin's lymphomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC615
Antibody Isotype:
IgG1, kappa
GMDN Code:
63898
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Immunoglobulin classes share the same basic four polypeptide chain structure of two heavy chains (five types) and two light chains - kappa and lambda. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. Antibodies against lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas.
Immunoglobulin classes share the same basic four polypeptide chain structure of two heavy chains (five types) and two light chains - kappa and lambda. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. Antibodies against lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas.
Immunoglobulin classes share the same basic four polypeptide chain structure of two heavy chains (five types) and two light chains - kappa and lambda. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. Antibodies against lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas.
LAG3 (Lymphocyte-activation gene 3) was discovered in 1990 and was previously designated as CD223. LAG3 is a cell surface molecule expressed by activated T cells, natural killer cells, B cells and plasmacytoiddendritic cells. It binds to major histocompatibility complex (MHC) class II molecules and serves as an immune checkpoint receptor. LAG3 negatively regulates cellular proliferation, activation and homeostasisof T cells, and plays a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in atolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 expression was detected in tumor infiltrating lymphocytes. IHC revealed LAG3 expression was distributed on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas. They were also detected in the tumor stroma as well as in the peritumoral tissue. LAG3 is the target of various drug development programs for cancer and autoimmune disorders. In soluble form, it is also being developed as a cancer drug in its own right.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC127
GMDN Code:
?
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
LAG3 (Lymphocyte-activation gene 3) was discovered in 1990 and was previously designated as CD223. LAG3 is a cell surface molecule expressed by activated T cells, natural killer cells, B cells and plasmacytoiddendritic cells. It binds to major histocompatibility complex (MHC) class II molecules and serves as an immune checkpoint receptor. LAG3 negatively regulates cellular proliferation, activation and homeostasisof T cells, and plays a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in atolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 expression was detected in tumor infiltrating lymphocytes. IHC revealed LAG3 expression was distributed on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas. They were also detected in the tumor stroma as well as in the peritumoral tissue. LAG3 is the target of various drug development programs for cancer and autoimmune disorders. In soluble form, it is also being developed as a cancer drug in its own right.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC127
GMDN Code:
?
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
LAG3 (Lymphocyte-activation gene 3) was discovered in 1990 and was previously designated as CD223. LAG3 is a cell surface molecule expressed by activated T cells, natural killer cells, B cells and plasmacytoiddendritic cells. It binds to major histocompatibility complex (MHC) class II molecules and serves as an immune checkpoint receptor. LAG3 negatively regulates cellular proliferation, activation and homeostasisof T cells, and plays a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in atolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 expression was detected in tumor infiltrating lymphocytes. IHC revealed LAG3 expression was distributed on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas. They were also detected in the tumor stroma as well as in the peritumoral tissue. LAG3 is the target of various drug development programs for cancer and autoimmune disorders. In soluble form, it is also being developed as a cancer drug in its own right.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC127
GMDN Code:
?
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC062
Antibody Isotype:
IgG1
GMDN Code:
57371
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC062
Antibody Isotype:
IgG1
GMDN Code:
57371
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC062
Antibody Isotype:
IgG1
GMDN Code:
57371
UKCA Status:
UKCA
CE-IVD Status:
IVDD
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Anti-Kappa recognizes surface immunoglobulin on normal and neoplastic B-cells, and has been indicated as a potential aid in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas, where the expression of a single light chain class is restricted. The determination of light chain ratio is critical in evaluating B-cell neoplasms, as the majority of B-cell lymphomas express either kappa or lambda light chains, while a mixture of kappa and lambda is characteristic of reactive proliferations. In paraffin-embedded tissue, Anti-Kappa displays strong staining of kappa-positive plasma cells, as well as cells that have absorbed exogenous immunoglobulins.
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone produced by the trophoblastic cells of the placenta after conception. Anti-hCG is useful for identifying trophoblastic tumours, such as choriocarcinoma. hCG is also a marker for non-trophoblastic tumours such as large cell carcinoma and lung adenocarcinoma.
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone produced by the trophoblastic cells of the placenta after conception. Anti-hCG is useful for identifying trophoblastic tumours, such as choriocarcinoma. hCG is also a marker for non-trophoblastic tumours such as large cell carcinoma and lung adenocarcinoma.
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone produced by the trophoblastic cells of the placenta after conception. Anti-hCG is useful for identifying trophoblastic tumours, such as choriocarcinoma. hCG is also a marker for non-trophoblastic tumours such as large cell carcinoma and lung adenocarcinoma.
Hepatitis B surface antigen (HBsAg) contains the large (L), middle (M), and small (S) surface proteins of the Hepatitis-B-Virus (HBV). It is the surface antigen of HBV, indicating current Hepatitis B infection. The body produces antibodies to HBsAg as part of the normal immune response to infection. Immunohistochemical staining for HBsAg in liver tissue is useful for the detection of HBV.
Hepatitis B surface antigen (HBsAg) contains the large (L), middle (M), and small (S) surface proteins of the Hepatitis-B-Virus (HBV). It is the surface antigen of HBV, indicating current Hepatitis B infection. The body produces antibodies to HBsAg as part of the normal immune response to infection. Immunohistochemical staining for HBsAg in liver tissue is useful for the detection of HBV.
Hepatitis B surface antigen (HBsAg) contains the large (L), middle (M), and small (S) surface proteins of the Hepatitis-B-Virus (HBV). It is the surface antigen of HBV, indicating current Hepatitis B infection. The body produces antibodies to HBsAg as part of the normal immune response to infection. Immunohistochemical staining for HBsAg in liver tissue is useful for the detection of HBV.
The HBcAg [IHC205] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of chronic HBV infection tissue within the context of antibody panels, the patients clinical history and other diagnositc tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC205
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Liver infected with Hepatitis B virus
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The HBcAg [IHC205] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of chronic HBV infection tissue within the context of antibody panels, the patients clinical history and other diagnositc tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC205
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Liver infected with Hepatitis B virus
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
The HBcAg [IHC205] antibody is intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in formalin-fixed, paraffin-embedded (FFPE) tissue sections using immunohistochemistry test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of chronic HBV infection tissue within the context of antibody panels, the patients clinical history and other diagnositc tests as evaluated by a qualified pathologist.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Applications:
IHC
Clone number:
IHC205
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Liver infected with Hepatitis B virus
Buffer:
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
Anti-Hairy Cell Leukemia stains various B-cells in the follicular mantle zone and virtually all cases of hairy cell leukemia. It also stains some high grade B-cell lymphomas.
Anti-Hairy Cell Leukemia stains various B-cells in the follicular mantle zone and virtually all cases of hairy cell leukemia. It also stains some high grade B-cell lymphomas.
Anti-Hairy Cell Leukemia stains various B-cells in the follicular mantle zone and virtually all cases of hairy cell leukemia. It also stains some high grade B-cell lymphomas.
Growth Hormone (GH or hGH) is a peptidic hormone produced by somatotrophs of the anterior pituitary gland. Anti-Growth Hormone stains somatotrophs in normal pituitary tissues, and is useful in identifying pituitary tumours and understanding pituitary disease or acromegaly. Studies have also found Anti-GH to stain non-pituitary cells, such as hepatocellular carcinoma and cutaneous lesions.
Growth Hormone (GH or hGH) is a peptidic hormone produced by somatotrophs of the anterior pituitary gland. Anti-Growth Hormone stains somatotrophs in normal pituitary tissues, and is useful in identifying pituitary tumours and understanding pituitary disease or acromegaly. Studies have also found Anti-GH to stain non-pituitary cells, such as hepatocellular carcinoma and cutaneous lesions.
Growth Hormone (GH or hGH) is a peptidic hormone produced by somatotrophs of the anterior pituitary gland. Anti-Growth Hormone stains somatotrophs in normal pituitary tissues, and is useful in identifying pituitary tumours and understanding pituitary disease or acromegaly. Studies have also found Anti-GH to stain non-pituitary cells, such as hepatocellular carcinoma and cutaneous lesions.
Rat HE4/WFDC2 ELISA Kit EZ-Set (DIY Antibody Pairs) (antibody pairs and standards for assay development). Quantitate Rat Wfdc2 in cell culture supernatants, serum and plasma (heparin, EDTA). Sensitivity: 10 pg/ml.
Product Type:
Antibodies Primary
Immunogen:
Expression system for standard: E.coli; Immunogen sequence: E31-F168
Applications:
ELISA
Biosite Brand:
BioSite ELISA
Species Reactivity:
rat
Cross Reactivity:
There is no detectable cross-reactivity with other relevant proteins.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glypican-3 (GPC3) is a GPI-anchored proteoglycan involved in cell division and growth regulation. Glypican-3 is a useful tumour marker, and its expression has been shown to be upregulated in hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumours, and Wilms' tumour. Patients with HCC have presented elevated levels of GPC3 in the neoplastic liver tissues and serum, levels which are higher than detected in cirrhotic liver or liver with focal lesions, including those with hepatic adenoma and dysplastic nodules. Glypican-3 is also overexpressed in testicular germ cell tumours of certain subtypes, such as yolk sac tumours and choriocarcinoma, and in embryonal tumours.
Glycophorin A (GPA) and Glycophorin B (GPB) are erythrocyte blood group determinants that minimize erythrocyte aggregation during the circulation of blood. Anti-Glycophorin A is useful for understanding erythroid cell development and identifying erythroid leukemias.
Glycophorin A (GPA) and Glycophorin B (GPB) are erythrocyte blood group determinants that minimize erythrocyte aggregation during the circulation of blood. Anti-Glycophorin A is useful for understanding erythroid cell development and identifying erythroid leukemias.
Glycophorin A (GPA) and Glycophorin B (GPB) are erythrocyte blood group determinants that minimize erythrocyte aggregation during the circulation of blood. Anti-Glycophorin A is useful for understanding erythroid cell development and identifying erythroid leukemias.
Glutamine Synthetase (GS-6 or GS) catalyzes the conversion of glutamate and ammonia to glutamine in the liver, and is expressed in pericentral hepatocytes, but not in periportal hepatocytes or in the mid-zonal. Anti-Glutamine Synthetase is useful in some hepatocellular carcinomas and many high grade dysplastic nodules, and therefore may be useful in recognizing these cases. A panel of antibodies against HSP70 (heat shock protein 70), GPC3, and glutamine synthetase is useful for differentiating dysplastic from early malignant hepatocellular nodules in cirrhosis. GS staining of hepatocellular lesions is useful for the differential diagnosis of focal nodular hyperplasia (FNH), hepatic adenoma (HCA), dysplastic nodules, and low grade hepatocellular carcinoma. FNH produces a “map-like” pattern when stained with Anti-Glutamine Synthetase. Conversely, HCA can stain negatively, produce border staining, or stain around the tumour veins.
Glutamine Synthetase (GS-6 or GS) catalyzes the conversion of glutamate and ammonia to glutamine in the liver, and is expressed in pericentral hepatocytes, but not in periportal hepatocytes or in the mid-zonal. Anti-Glutamine Synthetase is useful in some hepatocellular carcinomas and many high grade dysplastic nodules, and therefore may be useful in recognizing these cases. A panel of antibodies against HSP70 (heat shock protein 70), GPC3, and glutamine synthetase is useful for differentiating dysplastic from early malignant hepatocellular nodules in cirrhosis. GS staining of hepatocellular lesions is useful for the differential diagnosis of focal nodular hyperplasia (FNH), hepatic adenoma (HCA), dysplastic nodules, and low grade hepatocellular carcinoma. FNH produces a “map-like” pattern when stained with Anti-Glutamine Synthetase. Conversely, HCA can stain negatively, produce border staining, or stain around the tumour veins.
Glutamine Synthetase (GS-6 or GS) catalyzes the conversion of glutamate and ammonia to glutamine in the liver, and is expressed in pericentral hepatocytes, but not in periportal hepatocytes or in the mid-zonal. Anti-Glutamine Synthetase is useful in some hepatocellular carcinomas and many high grade dysplastic nodules, and therefore may be useful in recognizing these cases. A panel of antibodies against HSP70 (heat shock protein 70), GPC3, and glutamine synthetase is useful for differentiating dysplastic from early malignant hepatocellular nodules in cirrhosis. GS staining of hepatocellular lesions is useful for the differential diagnosis of focal nodular hyperplasia (FNH), hepatic adenoma (HCA), dysplastic nodules, and low grade hepatocellular carcinoma. FNH produces a “map-like” pattern when stained with Anti-Glutamine Synthetase. Conversely, HCA can stain negatively, produce border staining, or stain around the tumour veins.
Glucose transporter type I (GLUT1), also known as SCL2A1, is a glucose transporter present in the blood-brain barrier and erythrocytes. GLUT1 overexpression is associated with tumour progression or poor prognoses of bladder, breast, cervical, colon, and lung carcinomas, as well as mesothelioma. Anti-GLUT1 is useful for distinguishing malignant mesothelioma (GLUT1(+)) from reactive mesothelium (GLUT1(-)).
Glucose transporter type I (GLUT1), also known as SCL2A1, is a glucose transporter present in the blood-brain barrier and erythrocytes. GLUT1 overexpression is associated with tumour progression or poor prognoses of bladder, breast, cervical, colon, and lung carcinomas, as well as mesothelioma. Anti-GLUT1 is useful for distinguishing malignant mesothelioma (GLUT1(+)) from reactive mesothelium (GLUT1(-)).
Glucose transporter type I (GLUT1), also known as SCL2A1, is a glucose transporter present in the blood-brain barrier and erythrocytes. GLUT1 overexpression is associated with tumour progression or poor prognoses of bladder, breast, cervical, colon, and lung carcinomas, as well as mesothelioma. Anti-GLUT1 is useful for distinguishing malignant mesothelioma (GLUT1(+)) from reactive mesothelium (GLUT1(-)).
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein that is present in astrocytes and some ependymal cells of the central nervous system. In the peripheral nervous system, GFAP is present in Schwann cells, enteric glial cells, and satellite cells. Anti-GFAP staining is useful in differentiating neoplasms of astrocyte origin from other neoplasms in the central nervous system.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC584
Antibody Isotype:
IgG
GMDN Code:
57238
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Brain
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein that is present in astrocytes and some ependymal cells of the central nervous system. In the peripheral nervous system, GFAP is present in Schwann cells, enteric glial cells, and satellite cells. Anti-GFAP staining is useful in differentiating neoplasms of astrocyte origin from other neoplasms in the central nervous system.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC584
Antibody Isotype:
IgG
GMDN Code:
57238
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Brain
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein that is present in astrocytes and some ependymal cells of the central nervous system. In the peripheral nervous system, GFAP is present in Schwann cells, enteric glial cells, and satellite cells. Anti-GFAP staining is useful in differentiating neoplasms of astrocyte origin from other neoplasms in the central nervous system.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC584
Antibody Isotype:
IgG
GMDN Code:
57238
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Brain
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
GATA3 is a transcription factor important in cell proliferation, development, and differentiation. GATA3 is mostly observed in breast and urothelial carcinomas, and is rarely present in other cancers such as endometrial endometrioid adenocarcinoma. Among the breast carcinomas, GATA3 has a lower expression in luminal B subtype breast carcinoma. Studies have found GATA3 expression to be associated with ER (estrogen receptor), PR (progesterone receptor), and HER2 in breast cancer cases. Urothelial carcinomas stain positively for GATA3 in invasive or high grade tumours, therefore Anti-GATA3 is useful for carcinoma diagnosis when those of the breast and bladder are plausible.
GATA3 is a transcription factor important in cell proliferation, development, and differentiation. GATA3 is mostly observed in breast and urothelial carcinomas, and is rarely present in other cancers such as endometrial endometrioid adenocarcinoma. Among the breast carcinomas, GATA3 has a lower expression in luminal B subtype breast carcinoma. Studies have found GATA3 expression to be associated with ER (estrogen receptor), PR (progesterone receptor), and HER2 in breast cancer cases. Urothelial carcinomas stain positively for GATA3 in invasive or high grade tumours, therefore Anti-GATA3 is useful for carcinoma diagnosis when those of the breast and bladder are plausible.
GATA3 is a transcription factor important in cell proliferation, development, and differentiation. GATA3 is mostly observed in breast and urothelial carcinomas, and is rarely present in other cancers such as endometrial endometrioid adenocarcinoma. Among the breast carcinomas, GATA3 has a lower expression in luminal B subtype breast carcinoma. Studies have found GATA3 expression to be associated with ER (estrogen receptor), PR (progesterone receptor), and HER2 in breast cancer cases. Urothelial carcinomas stain positively for GATA3 in invasive or high grade tumours, therefore Anti-GATA3 is useful for carcinoma diagnosis when those of the breast and bladder are plausible.
Galectin-3 is a lectin involved in cell adhesion, macrophage activation, angiogenesis, metastasis, and apoptosis. Anti-Galectin-3 is useful for distinguishing between benign and malignant thyroid neoplasms. Galectin-3 is also useful for recognizing anaplastic large cell lymphoma.
Galectin-3 is a lectin involved in cell adhesion, macrophage activation, angiogenesis, metastasis, and apoptosis. Anti-Galectin-3 is useful for distinguishing between benign and malignant thyroid neoplasms. Galectin-3 is also useful for recognizing anaplastic large cell lymphoma.
Galectin-3 is a lectin involved in cell adhesion, macrophage activation, angiogenesis, metastasis, and apoptosis. Anti-Galectin-3 is useful for distinguishing between benign and malignant thyroid neoplasms. Galectin-3 is also useful for recognizing anaplastic large cell lymphoma.
Follicle-Stimulating Hormone (FSH) allows for progression of ovarian folliculogenesis, and enables Sertoli cell proliferation in the testis. Anti-FSH reacts with FSH-producing cells, and therefore FSH staining is useful for classifying pituitary cancers and understanding pituitary disease.
Follicle-Stimulating Hormone (FSH) allows for progression of ovarian folliculogenesis, and enables Sertoli cell proliferation in the testis. Anti-FSH reacts with FSH-producing cells, and therefore FSH staining is useful for classifying pituitary cancers and understanding pituitary disease.
Follicle-Stimulating Hormone (FSH) allows for progression of ovarian folliculogenesis, and enables Sertoli cell proliferation in the testis. Anti-FSH reacts with FSH-producing cells, and therefore FSH staining is useful for classifying pituitary cancers and understanding pituitary disease.
FOXP3 is a forkhead transcription factor family member which plays a key role in CD4+CD25+ regulatory T cell function and represents a specific marker for these cells. Specifically in IHC, FOXP3 is a marker for adult T-cell leukemia/lymphoma (ATLL). In normal lymphoid tissues, a T-cell subset in interfollicular areas shows nuclear staining. There are many characteristics of FOXP3s role in cancer, which involves tumour progression through the suppression of T-cell activity and oncogene suppression through suppressing the expression of HER2, Skp2, SATB1 and MYC oncogenes.
FOXP3 is a forkhead transcription factor family member which plays a key role in CD4+CD25+ regulatory T cell function and represents a specific marker for these cells. Specifically in IHC, FOXP3 is a marker for adult T-cell leukemia/lymphoma (ATLL). In normal lymphoid tissues, a T-cell subset in interfollicular areas shows nuclear staining. There are many characteristics of FOXP3s role in cancer, which involves tumour progression through the suppression of T-cell activity and oncogene suppression through suppressing the expression of HER2, Skp2, SATB1 and MYC oncogenes.
FOXP3 is a forkhead transcription factor family member which plays a key role in CD4+CD25+ regulatory T cell function and represents a specific marker for these cells. Specifically in IHC, FOXP3 is a marker for adult T-cell leukemia/lymphoma (ATLL). In normal lymphoid tissues, a T-cell subset in interfollicular areas shows nuclear staining. There are many characteristics of FOXP3s role in cancer, which involves tumour progression through the suppression of T-cell activity and oncogene suppression through suppressing the expression of HER2, Skp2, SATB1 and MYC oncogenes.
Flt-1, also known as Fms Related Tyrosine Kinase 1 or VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), is a tyrosine kinase involved in lymphangiogenesis, angiogenesis, and wound healing. It is present in endothelial cells, osteoblasts, placental trophoblasts, renal mesangial cells, and some hematopoietic stem cells. Anti-Flt-1/VEGFR1 is useful for identifying carcinomas of the larynx and esophagus.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC086
GMDN Code:
?
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Angiosarcoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Flt-1, also known as Fms Related Tyrosine Kinase 1 or VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), is a tyrosine kinase involved in lymphangiogenesis, angiogenesis, and wound healing. It is present in endothelial cells, osteoblasts, placental trophoblasts, renal mesangial cells, and some hematopoietic stem cells. Anti-Flt-1/VEGFR1 is useful for identifying carcinomas of the larynx and esophagus.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC086
GMDN Code:
?
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Angiosarcoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Flt-1, also known as Fms Related Tyrosine Kinase 1 or VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), is a tyrosine kinase involved in lymphangiogenesis, angiogenesis, and wound healing. It is present in endothelial cells, osteoblasts, placental trophoblasts, renal mesangial cells, and some hematopoietic stem cells. Anti-Flt-1/VEGFR1 is useful for identifying carcinomas of the larynx and esophagus.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC086
GMDN Code:
?
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Angiosarcoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Fibronectin is a glycoprotein that contributes to cell adhesion, migration, and metastasis. Renal cancer cells exhibit higher expression of fibronectin, therefore Anti-Fibronectin is useful for assessing the progression and aggressiveness of renal cancer cells.
Fibronectin is a glycoprotein that contributes to cell adhesion, migration, and metastasis. Renal cancer cells exhibit higher expression of fibronectin, therefore Anti-Fibronectin is useful for assessing the progression and aggressiveness of renal cancer cells.
Fibronectin is a glycoprotein that contributes to cell adhesion, migration, and metastasis. Renal cancer cells exhibit higher expression of fibronectin, therefore Anti-Fibronectin is useful for assessing the progression and aggressiveness of renal cancer cells.
Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
Cookies:
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.